"The Thompson Cancer Survival Center – Downtown facility has pioneered many advances in cancer treatment. Photodynamic therapy, which replaces invasive surgery with laser light treatment, was initially developed at Thompson Downtown. Thompson Downtown was the first clinical facility in the world to use TomoTherapy, the new third-generation stereotactic-guided radiation therapy and radiosurgery. The world’s first prostate, breast, lung, head and neck, spine, pediatric neurosurgery TomoTherapy patients were all treated at the facility. Thompson Downtown has the area’s first real-time prostate seed implant and has led with advances like respiratory gating, total skin electron therapy and 3-D imaging."

During the past decade, Thompson Cancer Survival Center conducted 43 clinical trials. In the 10-year time frame, 43 clinical trials started and 69 clinical trials were completed, i.e. on average, 160.5% percent of trials that started reached the finish line to date. In the past 5 years, 17 clinical trials started and 25 clinical trials were completed. i.e. 147.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Thompson Cancer Survival Center" #1 sponsor was "National Cancer Institute (NCI)" with 39 trials, followed by "SWOG Cancer Research Network" with 27 trials sponsored, "NSABP Foundation Inc" with 14 trials sponsored, "Alliance for Clinical Trials in Oncology" with 11 trials sponsored and "Radiation Therapy Oncology Group" with 11 trials sponsored. Other sponsors include 35 different institutions and companies that sponsored additional 29 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Thompson Cancer Survival Center" #1 collaborator was "National Cancer Institute (NCI)" with 68 trials as a collaborator, "NRG Oncology" with 16 trials as a collaborator, "SWOG Cancer Research Network" with 10 trials as a collaborator, "Cancer and Leukemia Group B" with 9 trials as a collaborator and "NCIC Clinical Trials Group" with 8 trials as a collaborator. Other collaborators include 49 different institutions and companies that were collaborators in the rest 33 trials.

According to Clinical.Site data, the most researched conditions in "Thompson Cancer Survival Center" are "Breast Cancer" (18 trials), "Recurrent Squamous Cell Lung Carcinoma" (8 trials), "Lung Cancer" (6 trials), "Prostate Cancer" (6 trials) and "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (6 trials). Many other conditions were trialed in "Thompson Cancer Survival Center" in a lesser frequency.

Most popular intervention types in "Thompson Cancer Survival Center" are "Drug" (112 trials), "Other" (60 trials), "Biological" (45 trials), "Radiation" (27 trials) and "Procedure" (19 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (31 trials), "Quality-of-Life Assessment" (20 trials), "Paclitaxel" (17 trials), "Carboplatin" (14 trials) and "Bevacizumab" (13 trials). Other intervention names were less common.

The vast majority of trials in "Thompson Cancer Survival Center" are 102 trials for "All" genders, 27 trials for "Female" genders and 9 trials for "Male" genders.

Currently, there are NaN active trials in "Thompson Cancer Survival Center". undefined are not yet recruiting, 15 are recruiting, 39 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 68 completed trials in Thompson Cancer Survival Center, undefined suspended trials, and 13 terminated clinical trials to date.

Out of the total trials that were conducted in Thompson Cancer Survival Center, 0 "Phase 1" clinical trials were conducted, 39 "Phase 2" clinical trials and 96 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".

Thompson Cancer Survival Center has several departments that took part in Clinical trials: "Thompson Cancer Survival Center at Methodist" - 2 trials